Latest Breaking News On - Last accessed - Page 2 : comparemela.com

Redefining Psoriasis Care: A Collaborative Journey for Better Patient Outcomes

Redefining Psoriasis Care: A Collaborative Journey for Better Patient Outcomes
hsj.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hsj.co.uk Daily Mail and Mail on Sunday newspapers.

United kingdomBristol myers squibbB patel bewleyWaise haiderKali rogersRoyal college of physicianBritish association of dermatologyCare information centreProgramme national specialtyBritish association of dermatologistsCare dermatology societyBristol myers squibb united kingdomBritish associationPrimary care dermatology societyImproving psychological well beingPsoriasis auckland

AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data

Building on expertise in RSV prevention, acquisition will accelerate ambition to deliver portfolio of protective interventions to address high unmet needs in infectious diseases .

New yorkUnited statesUnited kingdomAdrian kempAdam simpsonIskra reicIcosavax incIsochrone merger sub incHoldings incCompany secretaryDrug administrationInvestor relations teamUniversity of washingtonExchange commissionInstitute for protein designImmune therapies

AstraZeneca to acquire US-based clinical-stage biopharmaceutical company, Icosavax

AstraZeneca to acquire US-based clinical-stage biopharmaceutical company, Icosavax

New yorkUnited statesAdam simpsonIskra reicInstitute for protein designUniversity of washingtonIcosavax incImmune therapiesExecutive vice presidentChief executiveProtein designInfluenza respAcquired pneumonia requiring hospitalizationLast accessed

AstraZeneca : to acquire Icosavax, including potential first-in-class RSV and hMPV combination vaccine with positive Phase II data - Form 6-K -December 12, 2023 at 06:30 am EST

a4665w FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or.

United statesNew yorkUniversity of washingtonUnited kingdomAdam simpsonIskra reicAdrian kempInvestor relations teamRegulatory news serviceCompany secretaryCommission file numberIcosavax incHoldings incDrug administrationIsochrone merger sub incSecurities exchange

AstraZeneca to acquire Icosavax, including potential first-in-class RSV and hMPV combination vaccine with positive Phase II data

AstraZeneca has entered into a definitive agreement to acquire Icosavax, Inc. (NASDAQ: ICVX), a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform. The proposed acquisition will build on .

New yorkUnited statesUnited kingdomAdam simpsonIskra reicDrug administrationInstitute for protein designUniversity of washingtonHoldings incIsochrone merger sub incIcosavax incExchange commissionInvestor relations teamImmune therapiesExecutive vice presidentChief executive